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Abstract
Background: The objective of the current study was to define the impact of
albumin‐bilirubin (ALBI) grade on short‐ as well as long‐term outcomes among
patients with intrahepatic cholangiocarcinoma (ICC).
Methods: Patients who underwent hepatectomy for ICC between 1990 and 2016
were identified using an international multi‐institutional database. Clinicopathologic
factors including ALBI score were assessed using bivariate and multivariable analyses,
as well as standard survival analyses.
Results: Among 706 patients, 453 (64.2%) patients had ALBI grade 1, 231 (32.7%)
ALBI grade 2, and 22 (3.1%) had ALBI grade 3. After adjusting for all competing
factors, patients with ALBI grade 2/3 had higher odds of a prolonged length‐of‐stay
(>10 days, odds ratio [OR] = 2.37, 95% confidence interval [CI]:1.47‐3.80), periopera-
tive transfusion (OR = 2.15, 95% CI:1.45‐3.18) and 90‐day mortality (OR = 2.50, 95%
CI:1.16‐5.38). Median and 5‐year overall survival (OS) for the entire cohort was 41.5
months (IQR:15.7‐107.8) and 39.8%, respectively. Of note, median OS incrementally
worsened with increased ALBI grade: grade 1, 49.6 months (IQR:18.3‐NR) vs grade 2,
29.6 months (IQR:12.6‐98.4) vs grade 3, 16.9 months (IQR:6.5‐32.4; P < 0.001). On
multivariable analysis, higher ALBI grade remained associated with higher hazards of
death (grade 2/3: hazard ratio = 1.36, 95% CI:1.04‐1.78).
Conclusion: The ALBI score was associated with both short‐ and long‐term outcomes
following resection for ICC and could prove a useful surrogate marker to identify
patients at risk for adverse outcomes.
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1 | INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is a relatively rare cancer with
an increasing incidence in the United States (US) and worldwide over
the last three decades.1,2 Surgery remains the mainstay of treatment
and the only chance for cure among patients diagnosed with ICC.
Prognosis of patients remains dismal, however, even after curative‐
intent resection with a median survival ranging from 24 to 36
months.3,4 In addition, liver resection for ICC is associated with a high
perioperative morbidity reaching up to 45% and a mortality rate as
high as 5%.5 As such, development of risk stratification schemas is
necessary to improve preoperative patient selection and identify
patients who might benefit the most from surgery or other treatment
strategies in a multidisciplinary setting.
To date, there are only a few prognostic tools available for
patients with ICC.6-8 In addition, most of these tools rely on factors
known only after surgery as only a few models have utilized
preoperative factors to stratify the long‐term prognosis.6 Most
commonly, tumor‐associated factors such as tumor number, size,
major vascular invasion as well as serum biomarkers, such as the
carcinoembryonic antigen (CEA) and the cancer antigen (CA) 19‐9
have been correlated with clinical outcomes.6,7 Apart from tumor
factors, assessment of the underlying liver function is crucial in
determining the outcomes of patients undergoing liver surgery for
ICC.9-12 Of note, the albumin‐bilirubin (ALBI) grading system has
been proposed to provide a simple and objective method to evaluate
the liver function reserve and, in turn, predict patient outcomes
following liver surgery.13 Since its introduction in 2015, there has
been a growing interest of the prognostic utility of ALBI grade,
mainly focusing on patients undergoing surgery for hepatocellular
carcinoma (HCC).14,15 The prognostic utility of the ALBI score among
patients undergoing resection for ICC has, however, not been
assessed. As such, the objective of the current study was to examine
the ability of ALBI score to predict short‐ and long‐term outcomes
among patients undergoing resection for ICC. In addition, we sought
to investigate whether the ALBI grading system could stratify
prognosis of ICC patients in the presence or absence of cirrhosis.
2 | METHODS
2.1 | Study population and data collection
Patients undergoing curative‐intent liver resection for histologically
confirmed ICC between January 1990 and December 2016 were
identified in a multi‐institutional database incorporating data from 15
tertiary institutions (The Ohio State University Comprehensive
Cancer Center, Columbus, OH; Johns Hopkins Hospital, Baltimore,
MD; Stanford University, Stanford, CA; University of Virginia,
Charlottesville, VS; Winship Cancer Institute, Emory University,
Atlanta, GA; Fundeni Clinical Institute, Bucharest, Romania; Scientific
Institute San Raffaele, Vita‐Salute San Raffaele University, Milan,
Italy; University of Verona, Verona, Italy; Curry Cabral Hospital,
Lisbon, Portugal; Beaujon Hospital, Clichy, France; Erasmus
University Medical Centre, Rotterdam, Netherlands; University of
Ottawa, Ontario, Canada; Eastern Hepatobiliary Surgery Hospital,
Shanghai, China; Yokohama City University School of Medicine,
Yokohama, Japan; and Royal Prince Alfred Hospital, University of
Sydney, Sydney, Australia). Patients who did not undergo curative‐
intent resection or had missing data on the laboratory values of
interest, such as albumin and bilirubin, as well as missing follow‐up
data were excluded. The Institutional Review Board of all participat-
ing institutions approved this study.
2.2 | Variables and outcomes of interest
The primary outcome of interest was overall survival (OS); OS was
defined as the time interval between the date of hepatectomy for
ICC and the date of death or last follow‐up. Secondary outcomes
included complication rate (overall, major, minor), length‐of‐stay
(LOS) >10, perioperative transfusion, 90‐day mortality, and 30‐day
readmission rates. The primary independent variable was ALBI grade.
The ALBI score was calculated using the following formula: [log10
bilirubin (μmol/L) x 0.66] + [albumin (g/L) x −0.085], as previously
described.13 Similar to previous reports, patients were categorized
into three groups; grade 1 (≤−2.60), grade 2 (>−2.60 and ≤−1.39), and
grade 3 (>−1.39).13 Due to the limited number of patients with ALBI
grade 3, short‐ and long‐term outcomes of ALBI grade 2 and 3
patients were cumulatively assessed and compared with ALBI grade
1 patients.
Demographic and clinicopathologic data included age, sex, race,
American Society of Anesthesiologist (ASA) class, preoperative serum
level of bilirubin, albumin and carbohydrate antigen (CA) 19‐9,
presence of cirrhosis, type of resection (ie, minor, major), tumor
location (ie, unifocal, multifocal), tumor size, T stage, N stage, margin
status, morphological type (MF: mass‐forming; IG: intraductal
growth; PI: periductal infiltrating), tumor grade, presence of major
or microvascular invasion, receipt of adjuvant chemotherapy, and
LOS. Tumor T‐ and N stage were defined according to the American
Joint Committee on Cancer (AJCC) 8th edition staging manual.16
Major hepatectomy was defined as the resection of three or more
Couinaud segments.17 Major vascular invasion was defined as
invasion of the first‐ and second‐order branches of the portal vein
or hepatic arteries, or as invasion of one or more of the three hepatic
veins. In contrast, microvascular invasion was defined as intrapar-
enchymal vascular involvement identified on histological examina-
tion.16 Urinary tract or surgical site infections were categorized as
minor complications, whereas all other complications constituted
major complications, as previously reported.18
2.3 | Statistical analysis
Descriptive statistics were presented as median (interquartile range
[IQR]) and frequency (%) for continuous and categorical variables,
respectively. A logistic multivariable regression model was used to
examine the association between the ALBI grade and outcomes of
interest, including complications, LOS, perioperative transfusion,
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30‐day readmission, and 90‐day mortality. OS was calculated by
creating Kaplan–Meier curves and differences in survival between
different groups were assessed using the log‐rank test. The
association of clinicopathologic variables with OS was evaluated by
using a Cox proportional hazards model. Statistical significance was
assessed at α = 0.05. All statistical analyses were performed with the
SPSS, version 25 statistical package (IBM Corp, Armonk, NY).
3 | RESULTS
3.1 | Baseline characteristics of the entire cohort
A total of 706 patients with ICC met the predefined inclusion criteria
and were included in the analysis. Median patient age at the time of
surgery was 57.9 years (IQR: 49.3‐66.0) and more than half of
patients were male (n = 419, 59.4%). Only a minority of patients had
cirrhosis (n = 90, 13.8%). The median bilirubin, albumin, and CA19‐9
levels preoperatively were 0.9 mg/dL (IQR: 0.6‐1.4), 4.2 g/dL
(IQR: 3.8‐4.4), and 45.6 UI/mL (IQR: 17‐206), respectively. Overall,
453 (64.2%) patients had ALBI grade 1, 231 (32.7%) ALBI grade 2,
and 22 (3.1%) had ALBI grade 3 (Table 1). The majority of patients
had unifocal disease (n = 614, 87.1%) with a median tumor size of
6.0 cm (IQR: 4.0‐8.1). According to the 8th AJCC staging system,
56.5% (n = 399) of patients had T1a/T1b disease, while 22% (n = 155)
and 19.5% (n = 138) had N0 and N1 disease, respectively. In addition,
most patients had an R0 resection (n = 619, 88.3%), MF or IG
morphologic ICC type (n = 581, 88.8%), well to moderately differ-
entiated tumors (n = 574, 84.3%); only a small subset of patients had
major vascular invasion (n = 91, 12.9%). On histological examination,
27.1% (n = 190) of cases had microvascular invasion. Median LOS was
14 days (IQR: 9‐14). A minority of individuals received adjuvant
chemotherapy (n = 181, 26.2%).
3.2 | Short‐term outcomes
ALBI grade was associated with short‐term outcomes. Specifically,
after adjusting for age, sex, ASA class, cirrhosis, and type of resection,
patients with ALBI grade 2/3 had higher odds of a prolonged LOS
(>10 days, OR = 2.37; 95% CI, 1.47‐3.80; P < 0.001), as well as
perioperative transfusion (OR = 2.15; 95% CI, 1.45‐3.18; P < 0.001)
and 90‐day mortality (OR = 2.50; 95% CI, 1.16‐5.38; P = 0.019;
Table 2, Figure 1). ALBI grade 2/3 was also associated with higher
30‐day readmission on bivariate analysis (OR = 2.03; 95% CI, 1.03‐
3.98; P = 0.036).
3.3 | Long‐term outcomes
After a median follow‐up of 20.7 months (IQR: 10.8‐39.9), the median
and 5‐year OS for the entire cohort was 41.5 months (IQR: 15.7‐
107.8) and 39.8%, respectively. Of note, median OS incrementally
worsened with increased ALBI grade: ALBI grade 1, 49.6 months
(IQR: 18.3‐NR) vs ALBI grade 2, 29.6 months (IQR:12.6‐98.4) vs ALBI
grade 3, 16.9 months (IQR: 6.5‐32.4, P < 0.001; Figure 2). After
TABLE 1 Clinicopathologic features of patients (n = 706)
Variables Total, n (%)





Bilirubin (mg/dL), median (IQR) 0.9 (0.6, 1.4)
Albumin (g/dL), median (IQR) 4.2 (3.8, 4.4)
CA19‐9 (UI/mL), median (IQR) 45.6 (17, 206)
Cirrhosis 90 (13.8)
Type of resection
Minor resection 330 (47)




Tumor size, cm; median (IQR) 6.0 (4.0, 8.1)
AJCC 8th edition T stage
T1a/T1b 399 (56.5)
T2/T3/T4 307 (43.5)









MF, IG 581 (88.8)
PI, MF+PI 73 (11.2)
Grade
Well to moderate 574 (84.3)










LOS, median (IQR) 14 (9, 18)
ALBI grade
Grade 1 453 (64.2)
(Continues)
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stratifying by the presence of cirrhosis, cirrhotic patients with ALBI
grade 1 undergoing resection for ICC had better 5‐year OS compared
with ALBI grade 2/3 patients (54.5% vs 25.8%, P = 0.033; Figure 3A).
The same relationship was evident among noncirrhotic patients
(5‐year OS: 45.8% vs 35.8%, P = 0.013; Figure 3B).
On multivariable analysis, after controlling for competing factors,
higher ALBI grade remained associated with higher hazards of death
(referent grade 1: grade 2/3: hazard ratio [HR] = 1.36; 95% CI,
1.04‐1.78; P = 0.027). Perhaps not surprisingly, CA19‐9 >200 (HR =
2.49; 95% CI, 1.88‐3.30; P < 0.001), N1 disease (HR = 2.16; 95% CI,
1.40‐3.33; P < 0.001), higher T stage (referent T1: T2/T3/T4,
HR = 1.91; 95% CI, 1.36‐2.69; P < 0.001), R1/R2 resection (HR = 2.01;
95% CI, 1.28‐3.13; P = 0.002) and poor/undifferentiated tumor grade
(HR = 1.56; 95% CI, 1.09‐2.24; P = 0.014) were also associated with
poor OS (Table 3).
4 | DISCUSSION
ICC is a highly aggressive tumor with an increasing incidence over
the last few years, especially in Western countries.1,4 Despite
advances in the understanding of the biologic behavior of this tumor
and perioperative techniques, patients with ICC exhibit a 5‐year OS
of approximately 30% even after curative‐intent resection.1 To date,
several prognostic schemas and nomograms have been proposed to
stratify outcomes of patients with ICC.6-8 These have largely focused
on tumor‐specific factors, including tumor number, size, major
vascular invasion, lymph node status as well as serum CEA and
CA19‐9 levels.7,8 Apart from tumor‐specific characteristics, assess-
ment of underlying liver function is important to accurately predict
the risk of patients undergoing liver surgery for hepatobiliary
malignancies. The current study was important, because we
specifically examined the ability of a simple metric—the ALBI grade
—to predict the outcomes of patients undergoing surgery for ICC
using an international multi‐institutional database. Of note, patients
with ALBI grade 2 or 3 had higher odds of a prolonged LOS,
perioperative transfusion, and 90‐day mortality compared with ALBI
grade 1 patients. Perhaps of more interest, OS incrementally
worsened with increased ALBI grade, reaching a median OS as low
as 1.5 year among grade 3 patients. Importantly, the ALBI grade was
able to stratify prognosis of both cirrhotic and noncirrhotic patients.
To the best of our knowledge, this is the first study to validate the
prognostic utility of ALBI grade for both short‐ and long‐term
outcomes among patients undergoing surgery for ICC.
First proposed by Johnson et al13 in 2015, the ALBI grading
system attempted to assess hepatic function reserve of patients
diagnosed with HCC. The ALBI model is solely based on laboratory
parameters, namely albumin and bilirubin, without taking into
account the other factors included in the calculation of the Child‐
Pugh score, such as the prothrombin time and the presence of ascites
TABLE 1 (Continued)
Variables Total, n (%)
Grade 2 231 (32.7)
Grade 3 22 (3.1)
Abbreviations: AJCC, American Joint Committee on Cancer;
ALBI, albumin‐bilirubin; ASA, American Society of Anesthesiologist;
CA, Carbohydrate antigen; IG, intraductal growth; IQR, interquartile
range; LOS, length‐of‐stay; MF, mass‐forming; PI, periductal infiltrating
TABLE 2 Albumin‐bilirubin grade and short‐term outcomes
Variable Bivariate Multivariablea
(ALBI Grade 2/3 vs 1) OR, 95% CI P‐value OR, 95% CI P‐value
Any complication 1.17 (0.84, 1.63) 0.33 0.95 (0.67, 1.37) 0.80
Major complication 0.60 (0.38, 0.95) 0.020 0.79 (0.49, 1.27) 0.33
Minor complication 1.20 (0.35, 3.82) 0.73 0.73 (0.24, 2.24) 0.58
LOS >10 1.15 (0.81, 1.65) 0.42 2.37 (1.47, 3.80) <0.001
Perioperative transfusion 2.45 (1.71, 3.50) <0.001 2.15 (1.45, 3.18) <0.001
30‐d readmission 2.03 (1.03, 3.98) 0.036 1.02 (0.47, 2.25) 0.95
90‐d mortality 2.99 (1.50, 6.12) <0.001 2.50 (1.16, 5.38) 0.019
Abbreviations: ALBI, albumin‐bilirubin; CI, confidence interval; LOS, length‐of‐stay; OR, odds ratio
aAdjusted for age, gender, ASA class, cirrhosis, type of resection minor complications: SSI, UTI.
F IGURE 1 Association of albumin‐bilirubin (ALBI) grade with
short‐term outcomes
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or encephalopathy.9,13 Previous studies had examined the prognostic
accuracy of ALBI grade, mainly focusing on patients diagnosed with
HCC.13,15,19 In analyzing patients with HCC from an international
multi‐institutional database, Pinato et al15 reported that ALBI grade
stratified prognosis of patients with HCC across all tumor stages,
irrespective of the treatment employed (ie, surgery, transarterial
chemoembolization, or sorafenib). The authors suggested the routine
use of ALBI grade to stratify liver functional reserve among
patients.15 While several studies have examined ALBI grade and
HCC, there are little data on the prognostic impact of ALBI for other
hepatobiliary malignancies. Recently, Wang et al20 investigated the
utility of ALBI grade in predicting OS of patients with advanced
extrahepatic cholangiocarcinoma. The authors demonstrated that
ALBI grade could stratify the prognosis of patients, with a predictive
value greater than the Child‐Pugh score.20 To date, however, there
has been no study to validate the prognostic utility of the ALBI
metric among patients undergoing surgery for ICC. In the current
study, among 706 patients undergoing surgery for ICC, we noted that
patients with ALBI grade 3 had markedly worse prognosis compared
with ALBI grade 2 and grade 1 patients (median OS: 16.9 months vs
29.6 months vs 49.6 months; P < 0.001). In fact, patients with ALBI
grade 2/3 had a worse prognosis even after controlling for all
measured competing risk factors (HR = 1.36; 95% CI, 1.04‐1.78;
P = 0.027). Importantly, this difference was also evident among both
cirrhotic and noncirrhotic patients, thus demonstrating that this
metric had a good prognostic ability irrespective of the presence of
cirrhosis. As such, data from the current study strongly suggest that
ALBI score may be a useful preoperative tool to identify patients at
risk for adverse outcomes and, thus, help guide the management of
these patients.
Apart from long‐term survival, the ALBI grade has also been
associated with perioperative outcomes.18,21,22 A recent analysis of
F IGURE 2 Kaplan–Meier curve
demonstrating differences in overall
survival (OS) among patients with ALBI
grades 1, 2, and 3. ALBI, albumin‐bilirubin
F IGURE 3 Kaplan–Meier curve demonstrating differences in OS among patients with ALBI grade 1 vs grade 2/3 among cirrhotic (A) and
noncirrhotic patients (B). ALBI, albumin‐bilirubin; OS, overall survival
210 | TSILIMIGRAS ET AL.
the National Surgical Quality Improvement Program database from
our own group revealed that ALBI grade 2/3 was associated with
higher odds of posthepatectomy liver failure (PHLF; OR = 1.57, 95%
CI, 1.08‐2.27), bile leak (OR = 1.35; 95% CI, 1.02‐1.80), perioperative
transfusion (OR = 2.08; 95% CI, 1.69‐2.55), and 30‐day mortality
(OR = 2.40; 95% CI, 1.25‐4.60) following liver surgery for benign and
malignant diseases.18 In another study, Wang et al22 reported that
ALBI grade predicted both short‐ and long‐term outcomes of patients
undergoing liver resection for HCC with a higher accuracy than the
traditional Child‐Pugh score. Indeed, ALBI grade may overcome the
limitations of the traditional Child‐Pugh scoring system, namely the
use of interrelated variables (ie, albumin and ascites), the use of
subjective variables (ie, ascites and encephalopathy), and the
arbitrary selection of cut‐off values for continuous variables (ie,
bilirubin, albumin, and prothrombin time), thus eliminating “ceiling”
and “floor” effects.13-15 In line with the aforementioned findings, our
study revealed a strong association between an increased ALBI grade
and the short‐term outcomes of patients undergoing surgery for ICC;
patients with ALBI grade 2/3 had higher odds of prolonged LOS,
perioperative transfusion and 90‐day mortality compared with ALBI
grade 1 patients. Collectively, the data suggest—for the first time in
the literature—that ALBI grade could be an efficient tool in predicting
TABLE 3 Bivariate and multivariable analyses of survival
Bivariate Multivariable
Variables HR, 95% CI P‐value HR, 95% CI P‐value
Age
<60 Ref
>60 1.10 (0.87‐1.38) 0.424 ‐ ‐
Sex
Male Ref
Female 1.11 (0.88‐1.40) 0.348 ‐ ‐
ASA score
<2 Ref Ref
>2 1.29 (1.02‐1.65) 0.035 1.10 (0.79‐1.51) 0.58
CA 19‐9
<200 Ref Ref
>200 2.51 (1.96‐3.23) <0.001 2.49 (1.88‐3.30) <0.001
Cirrhosis
No Ref
Yes 0.88 (0.64‐1.21) 0.44 ‐ ‐
AJCC 8th edition N stage
N0 Ref Ref
N1 2.56 (1.80‐3.63) <0.001 2.16 (1.40‐3.33) <0.001
Nx 1.26 (0.93‐1.72) 0.133 2.23 (1.46‐3.40) <0.001
AJCC 8th edition T stage
T1a/T1b Ref Ref
T2/T3/T4 1.86 (1.49‐2.31) <0.001 1.91 (1.36‐2.69) <0.001
Margin status
R0 Ref Ref
R1/R2 1.64 (1.19‐2.25) 0.002 2.01 (1.28‐3.13) 0.002
Morphologic type
MF, IG Ref Ref
PI, MF+PI 1.56 (1.13‐2.15) 0.007 0.81 (0.51‐1.29) 0.384
Grade
Well to moderate Ref Ref
Poor to undifferentiated 1.63 (1.24‐2.16) 0.001 1.56 (1.09‐2.24) 0.014
Microvascular invasion
No Ref Ref
Yes 1.35 (1.06‐1.71) 0.015 0.76 (0.52‐1.11) 0.162
Adjuvant chemotherapy
No Ref
Yes 1.23 (0.96‐1.56) 0.098 ‐ ‐
ALBI grade
Grade 1 Ref Ref
Grade 2/3 1.47 (1.17‐1.84) 0.001 1.36 (1.04‐1.78) 0.027
Abbreviations: AJCC, American Joint Committee on Cancer; ALBI, albumin‐bilirubin; ASA, American Society of Anesthesiologist; CA, carbohydrate
antigen; IG, intraductal growth; MF, mass‐forming; PI, periductal infiltrating
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both short‐ and long‐term outcomes among patients undergoing
surgery for ICC.
The current study had certain limitations that should be
considered when interpreting the results. The retrospective nature
of the study may have introduced some selection bias (ie, selection of
patients for surgery). In addition, the lack of a comparison group (ie,
patients treated with treatments other than surgery) did not allow us
to draw definitive conclusions about the prognostic utility of the
ALBI grade among patients undergoing another type of therapy for
ICC; as such, the results should only be applied to a surgical
population. Finally, an analysis of the association between the ALBI
grade and specific complications of interest, such as PHLF or bile leak
was not feasible due to the large number of missing values for these
variables.
In conclusion, long‐term outcomes of patients undergoing
curative‐intent resection for ICC were relatively poor with a 5‐year
OS of approximately 40%. Prognosis of patients was associated with
tumor‐specific factors such as serum CA19‐9 levels, lymph node
status, T stage, and tumor differentiation. After controlling for these
factors, higher ALBI grade was independently associated with worse
outcomes. In fact, median OS incrementally worsened with increased
ALBI grade, with patients who had ALBI grade 3 surviving less than
1.5 years. This association was evident among both cirrhotic and
noncirrhotic patients. Apart from OS, higher ALBI grade also
predicted worse short‐term outcomes, including prolonged LOS,
perioperative transfusion, and 90‐day mortality. ALBI score may be a
useful surrogate marker to identify patients at risk for adverse
outcomes following resection for ICC and, thus, help guide the
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